Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

50%

4 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
4(100.0%)
4Total
Phase 4(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06051669Unknown

Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US

Role: lead

NCT04211805Unknown

Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B

Role: lead

NCT04201808Phase 4Unknown

Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides

Role: lead

NCT04237376Unknown

Chronic HBV Infection in Pregnant Women Taking TAF to Prevent Vertical Transmission

Role: lead

NCT03476083Phase 4Unknown

Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission

Role: lead

NCT01488526Phase 4Completed

Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus

Role: lead

NCT01715987Terminated

Tubular Function in Asian-American Patients Receiving TDF or ETV for HBV Treatment

Role: lead

NCT01743079Phase 4Completed

Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B

Role: collaborator

All 8 trials loaded